OncoSec Medical Incorporated (ONCS)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.70+0.02 (+0.89%)
At close: 4:00 PM EDT
People also watch:
INOIMUCRNNGALEMSTX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open1.72
Prev Close1.68
Bid1.60 x 900
Ask2.25 x 5000
Day's Range1.68 - 1.72
52wk Range1.36 - 6.94
1y Target EstN/A
Market Cap30.66M
P/E Ratio (ttm)-0.97
Beta3.06
Volume13,238
Avg Vol (3m)138,792
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • PR Newswire16 days ago

    OncoSec Announces Peer-Reviewed Publication of T-Cell Exhaustion Marker to Predict Response to Anti-PD-1 Therapy in Melanoma

    SAN DIEGO, Aug. 15, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced the publication ...

  • TheStreet.comlast month

    These 5 Stocks Are Poised for Breakouts

    Here's a technical look at how to trade five stocks that are ready to break out and trade higher from current levels.

  • PR Newswire2 months ago

    OncoSec Presents Significant Advancements in Electroporation Technology for Immunotherapy

    SAN DIEGO, June 28, 2016 /PRNewswire/ -- OncoSec Medical Incorporated ("OncoSec") (ONCS), a company developing DNA-based intratumoral cancer immunotherapies, presented recent advancements in electroporation (gene electro-transfer) for immunotherapy in two poster presentations at the American Association for Cancer Research (AACR) Special Conference on Engineering and Physical Sciences in Oncology in Boston. New data related to OncoSec's Tissue-based Real-time Adaptive Controlled Electroporation (TRACE™) technology and helical integrated applicator (Helix™) showed that these technologies have the potential to reduce procedural frequency as well as enhance usability by physicians. Together, these novel technologies may improve a patient's experience to gene electro-transfer and improve therapeutic outcomes, which will help broaden the adoption of gene-electro transfer technologies in immunotherapy.